Literature DB >> 20729961

A practical approach to treating autoimmune bullous disorders with systemic medications.

Anne Han1.   

Abstract

The bullous diseases comprise a heterogeneous group of skin disorders with distinct clinical and histological findings. They are characterized histologically by clefts at varying depths in the skin and are pathologically caused either by congenital defects or autoantibodies. Autoimmune bullous disorders are chronic conditions with significant morbidity and mortality in untreated patients. With the advent of immunosuppressive medications, mortality from these diseases has decreased significantly. However, complications from therapy itself are common causes of morbidity in these patients. Therefore, treatment of autoimmune bullous diseases is a challenge, as patients must remain on chronic medications with side effects that limit their use. This article aims to provide a practical approach to understanding the available medications for the treatment of autoimmune bullous diseases.

Entities:  

Year:  2009        PMID: 20729961      PMCID: PMC2924135     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  55 in total

Review 1.  Immunofluorescence in dermatology.

Authors:  D F Mutasim; B B Adams
Journal:  J Am Acad Dermatol       Date:  2001-12       Impact factor: 11.527

Review 2.  Tetracycline and niacinamide in the treatment of blistering skin diseases.

Authors:  G C Chaidemenos
Journal:  Clin Dermatol       Date:  2001 Nov-Dec       Impact factor: 3.541

3.  Dapsone hypersensitivity syndrome.

Authors:  R Prussick; N H Shear
Journal:  J Am Acad Dermatol       Date:  1996-08       Impact factor: 11.527

Review 4.  Management of autoimmune bullous diseases: pharmacology and therapeutics.

Authors:  Diya F Mutasim
Journal:  J Am Acad Dermatol       Date:  2004-12       Impact factor: 11.527

5.  Assessment of the risks of malignancy and lymphomas developing in patients using Sandimmune.

Authors:  I Cockburn
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

6.  Dermatitis herpetiformis responsive to systemic corticosteroids.

Authors:  P G Lang
Journal:  J Am Acad Dermatol       Date:  1985-09       Impact factor: 11.527

Review 7.  Sulfonamides and sulfones in dermatologic therapy.

Authors:  J E Bernstein; A L Lorincz
Journal:  Int J Dermatol       Date:  1981-03       Impact factor: 2.736

8.  Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus.

Authors:  Annette Czernik; Ernst H Beutner; Jean-Claude Bystryn
Journal:  J Am Acad Dermatol       Date:  2008-05       Impact factor: 11.527

9.  Treatment of linear IgA bullous dermatosis of childhood with flucloxacillin.

Authors:  Abdulmajeed Alajlan; Marwan Al-Khawajah; Omar Al-Sheikh; Fahad Al-Saif; Saleh Al-Rasheed; Ibrahim Al-Hoqail; Issam R Hamadah
Journal:  J Am Acad Dermatol       Date:  2006-04       Impact factor: 11.527

Review 10.  Azathioprine in dermatology.

Authors:  I R Younger; D W Harris; G B Colver
Journal:  J Am Acad Dermatol       Date:  1991-08       Impact factor: 11.527

View more
  2 in total

1.  Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent.

Authors:  Maria Victória Quaresma; Fred Bernardes Filho; Janaína Hezel; Murilo Calvo Peretti; Bernard Kawa Kac; Luna Azulay-Abulafia
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896

2.  A 72-year-old man with nonhealing facial erosions and bullae.

Authors:  Catherina X Pan; Catherine E Pisano; Mia S DeSimone; Vinod E Nambudiri
Journal:  JAAD Case Rep       Date:  2022-07-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.